Validating the performance of the mammary sentinel lymph node team

Euhus, David M.; Peters, G.; Leitch, A. Marilyn; Saboorian, Hossein; Mathews, Dana; Erdman, William A.; Anglin, Beth; Huth, James

doi:10.1002/jso.10078

Cited by 11 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A SLN was identified in 31/34 of MCTs in this study, which is comparable to the rate reported in human breast cancers (90% to 100%). 50,51 The procedure failed to identify an SLN in dogs with scar tissue either at the primary tumor site or in the expected region of the draining lymph node in our study. In the 4 dogs with a T0 tumor included in the study of Worley (2014), surgical scars were shorter than 3.5 cm, suggesting the prior execution of an excisional biopsy rather than a curative-intent surgery, as instead was the case of the two dogs included in our study with a recurrent tumor.…”

Section: Discussionmentioning

confidence: 56%

Biopsy of sentinel lymph nodes after injection of methylene blue and lymphoscintigraphic guidance in 30 dogs with mast cell tumors

et al. 2020

View full text Add to dashboard Cite

Objective -To report the outcomes associated with sentinel lymph nodes (SLNs) detection and extirpation guided by radionuclide and methylene blue injections in dogs with cutaneous and subcutaneous mast cell tumors (MCTs).Study Design -Clinical prospective cohort study. Animals -30 client-owned dogs with MCTs amenable to wide-margin excision, without evidence of distant metastasis and abnormal regional lymph nodes (RLNs).Methods -Technetium-99m and methylene blue were injected peritumorally. Dogs underwent pre-operative gamma camera scintigraphy, and an intraoperative gamma probe guided SLN extirpation. Outcomes included technical and surgical complications, number of SLNs, SLNs location respecting the expected RLN, and histopathology results.Results -SLN mapping was applied to 34 MCTs in 30 dogs without any complication.SLNs were not identified in 3/34 tumors, all with previous scar tissue. SLNs did not correspond to expected RLNs in 19/30 (63%) tumors. Histological examination confirmed an early or overt metastasis in 32/57 (56%) SLNs extirpated.Conclusion -SLN mapping and biopsy with radionuclide and injection of methylene blue was associated with low morbidity and allowed detection of SLNs in dogs with MCT at first presentation without scar tissue.Clinical significance -Incorporation of SLN mapping and extirpation allows for a personalized staging approach in dogs with MCT. The presence of scar tissue in dogs with recurrent tumors seems to be a limitation for SLN mapping with this technique.

show abstract

Section: Discussionmentioning

confidence: 56%

Biopsy of sentinel lymph nodes after injection of methylene blue and lymphoscintigraphic guidance in 30 dogs with mast cell tumors

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A recent survey on SLNB distributed by American Society of Breast Diseases Rapid Response Panel demonstrates that SLNB is considered to be the standard of care by 85% of the members who responded [75]. It has been suggested that surgeons should demonstrate an SLN identifi cation rate of > = 90% and a false negative rate of < = 5% before they offer SLNB without completion axillary dissection [76]. It is only after our validation study, we started doing SLNB therapeutically.…”

Section: Discussionmentioning

confidence: 99%